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Background: The sclerotium of Lignosus rhinocerotis (Cooke) Ryvarden (Tiger Milk mushroom) is used as a traditional
medicine to relieve cough, asthma and chronic hepatitis. The traditional uses of the sclerotium are presumably related
to its anti-inflammatory effect. The present study was carried out to evaluate the anti-inflammatory activity of the
sclerotial powder of L. rhinocerotis (Cooke) Ryvarden (Tiger Milk mushroom) cultivar TM02.
Methods: The anti-acute inflammatory activity of the sclerotial powder of L. rhinocerotis cultivar TM02 was investigated
using carrageenan-induced paw edema test while the inhibition of transudative and proliferative phases of chronic
inflammation were studied by cotton pellet induced granuloma model. Sprague Dawley rats were used in both studies.
The anti-inflammatory activity was also measured by inhibition of lipopolysaccharide induced TNF-alpha production in
RAW 264.7 macrophage cells.
Results: Cold water extract (CWE), hot water extract (HWE) and methanol extract (ME) of the sclerotial powder of
L. rhinocerotis cultivar TM02 possessed anti-acute inflammatory activity as was measured by carrageenan-induced paw
edema test, with CWE being the most potent. The acute anti-inflammatory activity of the cold water extract (CWE) was
mainly contributed by its high molecular weight (HMW) fraction isolated by Sephadex G50 gel filtration chromatography.
Its protein component was very potent in the inhibition of TNF-alpha production with an IC50 of 0.76 μg/ml. CWE at
200 mg/kg did not inhibit transudative and proliferative phase of chronic inflammation as shown by using the cotton
pellet induced granuloma model.
Conclusions: Our results suggested that most of the bioactive substance(s) contributed to the acute-inflammatory
activity of the sclerotial powder of L. rhinocerotis cultivar TM02 appear to be in the CWE, particularly its HMW
fraction. The anti-inflammatory activity of CWE was mainly contributed by the protein component of the high
molecular weight (HMW) fraction and it exhibited strong inhibitory effect on TNF-alpha production but the possibility
of synergistic effect between HMW, MMW and LMW fractions cannot be excluded. Future studies will provide new
insights into the anti-inflammatory activity of the sclerotial powder.
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Inflammation is a normal protective response to tissue in-
jury caused by physical trauma (cut, burn or bruise), nox-
ious chemicals, microbiologic agents or even autoimmune
disease [1]. Excessive inflammation may, however, lead to
tissue injury and when severe, cause physiological decom-
pensation, organ dysfunction and death cascade [2].
Non-steroidal anti-inflammatory drugs (NSAIDS) which
are effective for the treatment of inflammation are among
the most widely used drugs in the world [3]. However,
NSAIDs are associated with several side effects, especially
gastrointestinal toxicity including ulcerations, erosions,
life-threatening perforations or severe hemorrhage [4].
Therefore, there is a need to search for alternative anti-
inflammatory agent with reduced side effects.
Lignosus rhinocerotis (Cooke) Ryvarden (Tiger Milk
mushroom, synonym: Lignosus rhinocerus), is an import-
ant medicinal mushroom in Southeast Asia and China. In
Malaysia, it is also known as ‘cendawan susu rimau’ and is
the most popular medicinal mushroom used by the indi-
genous communities of Peninsular Malaysia to relieve
fever, cough, asthma, cancer, food poisoning and as a gen-
eral tonic [5,6]. In China, the sclerotium of the mushroom
is an expensive traditional medicine used for the treatment
of liver cancer, chronic hepatitis and gastric ulcers [7]. The
sclerotium of L. rhinocerotis is the part with medicinal
value. Unfortunately, the existence of this mushroom in
the jungle is always solitary and this makes collection of
large quantity of the mushroom’s sclerotia a difficult task.
Recently, Tan [8] reported a successful cultivation of the
mushroom in agar, solid and spawn medium with good
yield, thus making it possible to fully exploit its medicinal
and functional benefits. To date, anti-inflammatory activ-
ity of L. rhinocerotis has not been investigated. In the
present study, we report the investigation of the in vivo
anti-inflammatory activity of the extracts of sclerotial pow-
der of the mushroom using a rat model as well as the
in vitro inhibitory activity on lipopolysaccharide induced
TNF-alpha production in macrophage cells.
Methods
Preparation of the sclerotial powder of L. rhinocerotis
cultivar TM02
The sclerotia of L. rhinocerotis cultivar TM02 was pro-
vided by Ligno Biotech Sdn. Bhd. (Selangor, Malaysia) and
were identified by their internal transcribed spacer (ITS)
regions of the ribosomal DNA [9]. Sclerotia were freeze-
dried and milled into powder using 0.2 mm sieve. The
powder is light brown, dry fluffy with milk-like taste.
Extraction from the sclerotial powder of L. rhinocerotis
cultivar TM02
Cold water extract (CWE) was prepared by continual stir-
ring of the sclerotial powder for 24 h in distilled water at4°C. The extract was termed CWE TM02. Hot water ex-
traction of the sclerotial powder was performed using an
oil bath at 95°C to 100°C for 2 h. The extract was termed
HWE TM02. Methanol extraction was carried out by con-
tinual stirring of the powder in methanol at 25°C for 24 h.
The extract was termed ME TM02. All extractions were
performed with sample to solvent ratio of 1 g: 20 ml. After
each extraction, the mixture was centrifuged at 8000× g
for 30 min. The supernatant was filtered to remove insol-
uble materials. The aqueous extracts were freeze-dried
while the methanol extract of the sclerotial powder was
evaporated to dryness using at rotary evaporator at 37°C.Determination of total carbohydrate and protein contents
of the sclerotial extracts of L. rhinocerotis cultivar TM02
Total protein content was determined according to
Bradford method [10]. Bovine serum albumin was used
as a standard. Total carbohydrate content was deter-
mined by phenol sulphuric acid method according to
Dubois et al. [11]. Glucose standard curve was prepared
by using D-glucose.Fractionation of CWE of the sclerotial powder of L.
rhinocerotis
CWE TM02 was fractionated using Sephadex G-50
(Sigma-Aldrich, USA) Superfine column (v = 112 ml)
and eluted with 0.05 M ammonium acetate buffer at
0.5 ml/min. High molecular weight (HMW) fraction ap-
peared at void volume (mol. wt. >10 kDa dextran or
30 kDa protein) while low molecular weight (LMW)
fraction emerged at bed volume. Medium molecular
weight (MMW) fraction appeared between void and bed
volume. Protein and carbohydrate distribution of each
fraction and the pooled fractions (high, medium and low
molecular weight fractions) were determined by Bradford
and phenol sulphuric acid method, respectively, as
described earlier.Animals
Six male Sprague Dawley (SD) rats of 9 weeks old (240-
270 g) were used for each treatment of carrageenan in-
duced paw edema test while 8 weeks old (170-200 g) were
used for cotton pellet induced granuloma test. The animals
were supplied by Chenur Supplier (Selangor, Malaysia). The
animals were kept under standard conditions (temperature
at 22 ± 2°C, 12 h light, 12 h dark), and given food and water
ad libitum. Animals were acclimatised before use. The ani-
mals were handled according to the CIOMS guidelines
[12]. Experimental protocols reported in this study were ap-
proved by Institutional Animal Care and Use Committee,
University of Malaya (UM IACUC-Ethics reference no.
PM/16/11/2010/0812/FSY (R)).
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Carrageenan induced paw edema method was carried
out according to Arawwawala et al. [13], with modifica-
tions. CWE TM02 (25, 50, 100 or 200 mg/kg), HMW,
MMW and LMW fractions of the CWE (53, 35 and
112 mg/kg, respectively), HWE TM02 (200 mg/kg), ME
TM02 (200 mg/kg), reference drug (indomethacin at
10 mg/kg) or control group (6% sodium bicarbonate in
saline) was injected intraperitoneally into the rats (2 ml/
kg for each rat). The dosages used for HMW, MMW
and LMW fractions were calculated based on the frac-
tionated yield of each fraction from 200 mg/kg of CWE.
All extracts and the reference drug were prepared in 6%
sodium bicarbonate in saline. Intraperitoneal injection
was carried out one hour before the carrageenan treat-
ment. Edema was induced by a sub-plantar injection of
1.5% carrageenan in saline (0.2 ml) into the footpad of the
right hind paw of all animals. The right hind paw volumes
of these rats were measured using a plethysmometer (IITC
INC., USA) at hourly intervals up to 5 h. Paw edema vol-
ume was calculated by measuring paw volume increment:
(Vt - V0). Vt is the average volume of the right hind paw at
each time interval after carrageenan injection while V0 is
the average volume of the right hind paw before carra-
geenan injection. The percentage inhibition of edema vol-
ume at each hour compared to the control group was
calculated using the following formula:
Percentage inhibition ¼ A−Bð Þ=A½   100
Where A= (Vt − V0)control; B= (Vt − V0)treatment
The median inhibitory dose (ID50) for the inhibition of
inflammation at 3rd and 4th h (peak edema) after inflam-
mation induction was calculated.
Cotton pellet induced granuloma study
The inhibition effect of CWE on granuloma formation
in rats was examined as described by Barua et al. [14].
The rats (n = 6/group) were anesthetised with ketamine
(45 mg/kg) and xylazine (4.5 mg/kg) and shaved on their
backs. An incision was made on the back followed by
subcutaneously implantation of sterilised cotton pellets
weighing 20 ± 1 mg. The animals were fed orally with
CWE at 200 mg/kg from day 1 to 7. Control group re-
ceived 6% sodium bicarbonate in saline at 10 ml/kg. Indo-
methacin group (1 mg/kg) was fed orally every 2 days. On
the 8th day, the animals were euthanised using an overdose
of carbon dioxide. The cotton pellets surrounded by
granulomatous tissue were removed and made free from
extraneous tissues. The wet pellets were weighed and
dried at 60°C overnight to a constant weight. The mean
dry weight of granulomatous tissue (after subtracting the
weight of cotton pellet) was determined. The percentageinhibition was calculated by comparing the mean dry and
wet weight of the treated group with the control group.Isolation of the protein and non-protein components
(P-HMW and NP-HMW) of the HMW fraction
The proteins of HMW fraction (P-HMW) were precipi-
tated with ammonium sulphate, which was added grad-
ually to the HMW fraction at 4°C until 100% saturation
was reached. After stirring for 1 h, the solution was cen-
trifuged to collect the precipitated proteins. The super-
natant was desalted by Sephadex G-50 (Sigma-Aldrich,
USA) chromatography (column size v = 228.3 ml) and
eluted with 0.05 M ammonium acetate buffer at 2 ml/
min. The fractions collected were then freeze-dried. The
sample was termed non-protein component of the
HMW fraction (NP-HMW). The protein pellet was dis-
solved in MiliQ water and desalted with Vivaspin 15R
(5000 MWCO), and was termed protein component of
the HMW fraction (P-HMW). The protein and carbohy-
drate contents of P-HMW and NP-HMW were deter-
mined by Bradford and phenol sulphuric acid method,
respectively, as described earlier.Determination of the glucan content of the HMW fraction
and its protein and non-protein components isolated by
ammonium sulfate precipitation
The glucan content of HMW fraction as well as its pro-
tein and non-protein components was determined by
Mushroom and Yeast Glucan Assay Kit (Megazyme
International Ireland Ltd, Bray Co, Wicklow, Ireland)
according to manufacturer’s instructions. Briefly, total
glucan plus D-glucose in oligosaccharides, sucrose and
free D-glucose were solubilised in concentrated hydro-
chloric acid (37%) and hydrolysed by 1.3 M HCl at 100°
C for 2 h. 2 M KOH was then added to neutralise the
hydrolysates. Hydrolysis to D-glucose was completed by
incubation with a mixture of highly purified exo-1,3-β-
glucanase and β-glucosidase. The hydrolysates were
then incubated with glucose oxidase/peroxidase mix-
ture (GOPOD) reagent. Absorbance was measured at
510 nm against the GOPOD reagent blank and com-
pared to D-glucose standard to calculate percentage of
total glucan plus oligomers etc. Alpha glucan plus D-
glucose in sucrose and free D-glucose was solubilised
and hydrolysed in 2 M KOH and amyloglucosidase
(1630 U/ml) plus invertase (500 U/mL). The hydroly-
sates were incubated with GOPOD reagent. Absorbance
was measured at 510 nm against GOPOD reagent blank
and compared to D-glucose standard to calculate per-
centage of alpha glucan plus oligomers etc. Percentage
of beta glucan content was obtained by subtracting per-
centage of total glucan plus oligomers etc. and alpha
glucan plus oligomers.
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production
The murine macrophage cell line RAW 264.7 (ATCC®
TIB-71™) was grown in DMEM (ATCC) supplemented
with 10% heat inactivated FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin, at 37°C in a humidified 5%
CO2 incubator. To examine cell viability, the cells
(seeded at 2 × 105 cells/well in 96-well plate) was pre-
treated with the respective extracts for 1 h and then
stimulated with 0.10 μg/ml LPS for 24 hours. Medium
was then removed and 100 μl of 0.5 mg/ml MTT was
added to each well and incubated for 1.5 h at 37°C in
the dark. After removing the supernatant, 100 μl DMSO
was added to the cells to dissolve the formazan crystals.
The absorbance of each group was measured by a mi-
croplate reader at 570 nm. Absorbance of treatment
groups was normalized to the LPS-treated control, and
expressed as percentage viability.
Measurement of inhibition of TNF-alpha production
RAW 264.7 macrophages were cultured in 96-well plate
with CWE, HMW, MMW, LMW and NP-HMW at 12.50,
25.00, 50.00, 75.00 and 100.00 μg/ml, and P-HMW at
0.10, 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00 and 2.50 μg/ml
for 1 h, and then incubated with 0.10 μg/mL LPS for 24 h.
Supernatants were obtained and frozen at −80°C until ana-
lysis. TNF-alpha in the culture medium was determined
by TNF-α mouse ELISA kit (Novex®) according to the
manufacturer’s recommended protocols. The ELISA plates
were read using a microplate reader at 450 nm. The result
was expressed in percentage of inhibition of TNF-alpha
production of the various treatment groups as compared
to LPS stimulated group without pre-treatment, and IC50
values were then calculated.
Statistical analysis
All data were expressed as mean ± S.E.M. and analysed
using One-way Analysis of Variance (ANOVA). Statis-
tical differences between the means of control and
treatment groups were determined using Dunnett’s t
(two-sided) test. In case of variance heterogeneity,
Dunnett’s T3 test was used. The homogeneity of vari-
ances was calculated using Levene statistics. Statistical
differences between results on 200 mg/kg CWE TM02
and ME TM02 as well as HWE TM02 were analysed
using Independent Samples t-test. Results were consi-
dered significant at p < 0.05.
Results
Determination of total carbohydrate and protein content
of the various sclerotial extracts
The carbohydrate content of CWE, HWE and ME were
determined to be 68.4%, 92.2% and 12.8% by dry weight(w/w), respectively, and the protein content were found to
be 2.0%, 0.2% and 0.2% by dry weight (w/w), respectively.
Extraction Yield of CWE TM02, HWE TM02 and ME TM02
The extraction yield of CWE, HWE and ME were 20%,
37% and 5% by dry weight (w/w), respectively.
Fractionation of CWE
CWE was separated into HMW, MMW and LMW frac-
tions by Sephadex G-50 gel filtration chromatography
(Figure 1). The HMW fraction consisted of 4% protein
and 79% carbohydrate by dry weight (w/w). The MMW
fraction consisted of 1% protein and 54% carbohydrate by
dry weight (w/w), while the LMW fraction contained 0.3%
of protein and 24% carbohydrate by dry weight (w/w).
Carrageenan induced paw edema study
CWE was found to reduce carrageenan induced paw
edema in SD rats at all doses employed (25, 50, 100 and
200 mg/kg) after 1–5 h of carrageenan injection
(Table 1). CWE at 50, 100 and 200 mg/kg displayed sig-
nificant inhibition of paw edema as compared to control
group from 2nd to 5th h post carrageenan injection (p <
0.05). A significant inhibition of paw edema formation
was observed in the rat treated with CWE at 200 mg/kg
at first hour post carrageenan injection. Paw edema in-
hibition in dose dependent manner was observed in rat
treated with CWE at all doses employed after 2–5 h of
carrageenan injection.
Paw edema of SD rat treated with CWE reached max-
imal size at 3rd to 4th h post carrageenan injection. The
median inhibitory doses (ID50) of the CWE for the sup-
pression of paw edema at the 3rd and 4th h were both
88 mg/kg. CWE at 200 mg/kg showed paw edema inhib-
ition which was higher than inhibition caused by the
standard drug indomethacin at 10 mg/kg, after 1–5 h of
carrageenan injection. HMW fraction of CWE (53 mg/
kg) showed inhibitory effect to paw edema formation in
SD rats which was higher than MMW (35 mg/kg) and
LMW (112 mg/kg) fractions of the same extract.
HWE and ME at 200 mg/kg displayed paw edema in-
hibitory activity which was significantly lower (Inde-
pendent sample t-test, p < 0.05) than CWE at the same
dosage (after 1–5 h of carrageenan injection), with ME
TM02 being the least potent.
Cotton pellet induced granuloma study
CWE at 200 mg/kg did not significant cause suppression
of the wet and dry weight of granuloma as compared to
the control group (Table 2). However, the wet and dry
weight of granuloma from rats treated with 1 mg/kg
indomethacin for every 2 days were significantly reduced
by 20.8% and 20.3%, respectively.
Figure 1 Sephadex G-50 superfine gel filtration chromatography of the cold water extract (CWE). The cold water extract (CWE, 500 mg
dissolved in 5.6 ml milliQ water) was loaded to the column (v = 112 ml) and 3 ml per fraction were collected into each test tube.
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fraction
The HMW fraction was subjected to 100% ammonium
sulphate precipitation to yield the protein (P-HMW) and
non-protein components (NP-HMW). The protein com-
ponent consisted of protein and large amount of carbo-
hydrate, with a carbohydrate to protein ratio of 8. About
79.7% of the carbohydrate was alpha glucan and oligo-
mers etc. and only 1.1% was beta glucan. On the other
hand, the non-protein component (NP-HMW) was
99.3% carbohydrate, of which 57.5% was alpha glucan
and oligomers etc. and 3.2% was beta glucan.
Inhibition of TNF-alpha production
The CWE and its high and medium molecular weight frac-
tions (HMW and MMW) all exhibited dose-dependentTable 1 Effects of sclerotial extracts of L. rhinocerotis cultivar
Group Dose (mg/kg
body weight) 1st hour 2nd hou
Control 0.28 ± 0.02 0.76 ± 0.
CWE TM02 25 0.25 ± 0.02 (12) 0.52 ± 0.04*
50 0.18 ± 0.02 (36) 0.40 ± 0.07*
100 0.18 ± 0.01 (35) 0.22 ± 0.04*
200 0.11 ± 0.03* (61) 0.13 ± 0.03*
HMW 53** 0.11 ± 0.02* (63) 0.12 ± 0.02*
MMW 35** 0.16 ± 0.03* (44) 0.30 ± 0.04*
LMW 112** 0.23 ± 0.03 (20) 0.46 ± 0.05*
ME TM02 200 0.24 ± 0.05 (15) 0.68 ± 0.04
HWE TM02 200 0.20 ± 0.03 (31) 0.41 ± 0.06*
Indomethacin 10 0.18 ± 0.03 (35) 0.23 ± 0.03*
Each value is mean ± S.E.M of six rats. *p < 0.05, compared with control using Dunn
inhibition of edema volume at each hour as compared to the control group. **Amo
chromatography. CWE-cold water extract; HWE-hot water extract; ME-methanol extr
fraction; LMW-low molecular weight fraction.TNF-alpha inhibition activity (Figure 2, in all experiments,
cell viability ≥ 75%). The half maximal inhibitory concen-
tration (IC50) of CWE, HMW and MMW was 32.0, 16.0
and 56.0 μg/ml, respectively. The low molecular weight
fraction did not exhibit the inhibitory activity. The protein
component of the HMW exhibited very potent TNF alpha
inhibition activity with IC50 of 0.76 μg protein/ml (data
not shown), but the non-protein component did not ex-
hibit any inhibitory activity.
Discussion
The medicinal mushroom L. rhinocerotis has been used
extensively by the indigenous people from Peninsular
Malaysia. Usually, the sclerotium of the mushroom is
grated on a hard surface with some water, and the result-
ing aqueous mixture is further diluted with water andTM02 on carrageenan induced paw edema in rats
Paw edema volume (ml)
r 3rd hour 4th hour 5th hour
04 0.85 ± 0.03 0.90 ± 0.04 0.86 ± 0.04
(32) 0.70 ± 0.03 (18) 0.70 ± 0.03* (22) 0.65 ± 0.04* (25)
(48) 0.50 ± 0.06* (42) 0.51 ± 0.05* (44) 0.46 ± 0.05* (47)
(71) 0.33 ± 0.04* (62) 0.41 ± 0.03* (55) 0.35 ± 0.02* (60)
(83) 0.10 ± 0.03* (88) 0.11 ± 0.03* (88) 0.10 ± 0.03* (89)
(84) 0.12 ± 0.02* (86) 0.09 ± 0.02* (90) 0.08 ± 0.02* (91)
(61) 0.35 ± 0.05* (65) 0.51 ± 0.05* (43) 0.44 ± 0.03* (49)
(39) 0.51 ± 0.05* (41) 0.51 ± 0.04* (43) 0.47 ± 0.04* (46)
(11) 0.78 ± 0.04 (9.0) 0.73 ± 0.04* (19) 0.69 ± 0.03* (20)
(46) 0.50 ± 0.05* (42) 0.49 ± 0.04* (46) 0.47 ± 0.03* (45)
(69) 0.26 ± 0.03* (69) 0.37 ± 0.03* (59) 0.34 ± 0.03*(57)
ett’s t (two-sided) test. Values given in parentheses represent the percentage
unt isolated from 200 mg/kg of CWE TM02 using sephadex G-50 gel filtration
act; HMW-high molecular weight fraction; MMW-medium molecular weight




Wet weight (mg) Dry weight (mg)
6% sodium bicarbonate (control) - 281.0 ± 13.8 39.6 ± 1.4
CWE TM02 200 281.2 ± 13.9 40.2 ± 2.4
Indomethacin 1 222.7 ± 14.3* (20.8%) 31.5 ± 2.6* (20.3%)
Values are mean ± S.E.M. Values given in parentheses represent percentage of inhibition. *Significant difference with control (ANOVA, Dunnett’s t (two-sided)
test, p < 0.05).
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of preparation mimic cold and hot water extract and
hence cold and hot water extractions were used in the
study in the investigation of anti-inflammatory activity of
the mushroom. The methanol extraction was used to in-
vestigate if the non-polar, water insoluble substances also
contribute to the anti-inflammatory activity.
Carrageenan induced rat hind paw edema has been
widely used for evaluation of anti-inflammatory drugs as
the relative potency estimates obtained from most drugs
tend to reflect clinical experience [16]. Inflammation in-
duced by carrageenan is acute, well researched and
highly reproducible [17]. The course of carrageenan in-
duced paw edema consisted of three phases [18]. The
first phase is mediated by histamine and serotonin
during the first hour, after which the increased vascular
permeability is maintained by kinin (secondary phase)Figure 2 The inhibitory effect of the cold water extract (CWE) and its
in RAW 264.7 cells.release up to 2.5 h [18]. From 2.5-6.0 h, the mediator ap-
pears to be a prostaglandin (final phase), release of
which is closely associated with migration of leucocytes
into the inflamed site [18].
The cold water extract exhibited anti-acute inflamma-
tory activity by reducing paw edema induced by carra-
geenan at all the doses tested (25, 50, 100 and 200 mg/kg),
during all three phases of edema development. Significant
paw edema inhibition in a dose dependent manner was
observed in rats treated with CWE from 25–200 mg/kg
(p < 0.05) at 2nd -5th h post carrageenan injection. The
anti-inflammatory pattern of CWE was similar to 10 mg/
kg of indomethacin (an NSAID) in which all three phases
of edema development induced by carrageenan were also
inhibited. The CWE at 200 mg/kg showed greater extent
of paw edema inhibition than that of 10 mg/kg indometh-
acin during all three phases of edema development.HMW and MMW fractions on LPS-induced TNF-alpha production
Lee et al. BMC Complementary and Alternative Medicine 2014, 14:359 Page 7 of 8
http://www.biomedcentral.com/1472-6882/14/359Lakshimi et al. [19] reported that ethanol extract of
Ganoderma lucidum mycelium at 1000 mg/kg showed
65% paw edema inhibition after 3 h of carrageenan in-
jection whereas CWE at lower dosage (200 mg/kg) gave
88% paw edema inhibition. Beta glucan rich extract
from Caripia montagnei at 50 mg/kg significantly re-
duced the paw edema induced by carrageenan at 71%
[20]. It should be noted, however, that the experimental
design of the above mentioned findings (including ours)
vary from one another and as such, it is not possible to
make quantitative comparison.
In 200 mg/kg of cold water extract, the amount of the
HMW, MMW and LMW fractions were 53 mg/kg, 35
and 112 mg/kg, respectively. Paw edema inhibition activ-
ity of the HMW fraction at 53 mg/kg dosage was com-
parable to that of 200 mg/kg CWE, whereas 35 mg/kg of
MMW and 112 mg/kg of LMW fraction both showed
substantially lower anti-inflammatory activity. This
showed that the anti-inflammatory activity of CWE is
mainly contributed by HMW fraction but the possibility
of synergistic effect between HMW, MMW and LMW
fractions cannot be excluded. CWE also exhibited
in vitro anti-inflammatory activity as shown by its inhibi-
tory effect on TNF alpha production in LPS-induced-
macrophages, and both its HMW and MMW fractions
exhibited strong inhibitory activity.
The nature of the active principle in the CWE causing
anti-inflammatory activity has yet to be elucidated. A pos-
sible candidate is the polysaccharides-protein complexes
or polysaccharides found in the extract. It has been re-
ported that the anti-inflammatory properties of Phellinus
rhinosus (Berk) and Poria cocos cultured mycelia were at-
tributed to the polysaccharide-protein complex and water-
soluble polysaccharide, respectively [21,22]. The HMW
fraction consists of 4% protein and 79% carbohydrates.
The protein component isolated by ammonium sulfate
precipitation, exhibited very potent TNF alpha inhibitory
activity but the nature of the bioactive protein(s) that
exhibit the anti-inflammatory activity in the protein
component are yet to be elucidated. Since the protein
component contained large amount of carbohydrate (8
parts of carbohydrate to 1 part of protein, mostly alpha
glucan), the polysaccharide-protein complex may play a
role in the anti-inflammatory effect. On the other hand,
the non-protein component that was essentially carbo-
hydrate (and mainly alpha glucan, with only 3.2% beta
glucan) did not inhibit TNF-alpha production and
hence was devoid of anti-inflammatory activity.
The hot water extract (HWE) and methanol extract
(ME) at the dosage of 200 mg/kg were far less effective
in reducing paw edema induced by carrageenan in all
three phases of edema development when compared to
CWE, at the same dosage. The extraction yield of CWE,
HWE and ME were 20% (w/w), 37% (w/w) and 5% (w/w),respectively. The major anti-inflammatory principle(s) of
the sclerotial powder of L. rhinocerotis cultivar TM02 are
in the cold water extract, in particular, its high molecular
weight fraction (HMW). The HWE exhibited weaker anti-
inflammatory activity but because of its high yield it also
contains substantial amount of anti-inflammatory principle.
The yield of ME was so low that it contains only negligible
amount of the bioactive substance.
Granulomatous inflammation is a focal chronic in-
flammatory response to tissue injury evoked by a poorly
soluble substance characterised by the accumulation and
proliferation of leukocytes, principally of the mono-
nuclear type [23]. Cotton pellet induced granuloma test
is widely used to assess transudative, exudative and pro-
liferative phase of inflammation [24]. In this study, CWE
at 200 mg/kg did not show reduction of wet and dry
weight of implanted cotton pellet, indicating that it
might not inhibit the transudative and proliferative
phase of chronic inflammation.
Conclusion
All three extracts of the sclerotial powder of L. rhinocer-
otis cultivar TM02 possess anti acute-inflammatory ef-
fect but most of the bioactive substance(s) appear to be
extractable by cold water. The anti-inflammatory activity
of the cold water extract (CWE) is mainly contributed
by its high molecular weight (HMW) fraction, in par-
ticular its protein component, which was very potent in
the inhibition of TNF-alpha production with an IC50 of
0.76 μg/ml. However, the possibility of synergistic effect
between HMW, MMW and LMW fractions cannot be
excluded. Cold water extract at 200 mg/kg did not in-
hibit transudative and proliferative phase of chronic
inflammation.
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